Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Suicide and Life-Threatening Behavior Suicide and Life-Threatening Behavior Suicide and Life-Threatening Behavior is a peer-reviewed academic journal published six times per year by Wiley-Blackwell on behalf of the American Association of Suicidology. The journal was established in 1971 by Edwin S. Shneidman. Its current editor-in-chief is Thomas Joiner (Florida State University). The journal covers scientific research on suicidal and other life-threatening behaviors, including risk factors for suicide, ethical issues in intervention research, and mental health needs of those bereaved by suicide. According to the "Journal Citation Reports", the journal has a 2011 impact factor of 1.333, ranking it 45th out of 125 journals in